Drugs / CYP-1020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT01363349 | May 2011 → Mar 2013 | schizophrenia | BioLineRx, Ltd. | Terminated | Missed primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-01-23 | BioLineRx, Ltd. | BioLineRx Announces Cypress Bioscience’s and Royalty Pharma’s Commitment to the Development of the BL-1020 (CYP-1020) Program biolinerx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYP-1020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01363349 ↗ |
| Route | Oral | “orally available” NCT01363349 ↗ |